Utilization of LCP-Tacrolimus (Envarsus XR) in Simultaneous Pancreas and Kidney Transplant Recipients

Torabi, Julia; Campbell, Alesa; Ajaimy, Maria; Rocca, Juan P.; Graham, Jay A.

doi:10.31486/toj.18.0011

Cited by 6 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data are available only for SPK transplantation and show that once‐a‐day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long‐acting tacrolimus. 270 , 271 , 272 , 273 …”

Section: Discussionmentioning

confidence: 99%

“…Reported experience with the use of once‐a‐day tacrolimus formulation in pancreas transplantation is limited. Data are available only for SPK transplantation and show that once‐a‐day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long‐acting tacrolimus 270–273 …”

Section: Discussionmentioning

confidence: 99%

“…Data are available only for SPK transplantation and show that once-a-day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long-acting tacrolimus. [270][271][272][273] In comparison with cyclosporine, experts agreed that the use of tacrolimus is prevalent in all pancreas transplant categories and is associated with superior immunologic outcomes. No conclusion could be drawn on the comparative efficacy of once-a-day vs. twice-a-day tacrolimus formulations due to lack of supporting data.…”

Section: Cni-based Regimenmentioning

confidence: 99%

See 2 more Smart Citations

First World Consensus Conference on pancreas transplantation: Part II – recommendations

Boggi

Vistoli

Andrès

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Cni-based Regimenmentioning

confidence: 99%

See 1 more Smart Citation

First World Consensus Conference on pancreas transplantation: Part II – recommendations

Boggi

Vistoli

Andrès

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Notably, another extended-release formulation (Advagraf/Astagraf) has been commonly used in medication adherence research. Reports in the literature have documented the benefits of the extended-release formulation of tacrolimus, with evidence of increased medication adherence in kidney and kidney-pancreas transplant recipients [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial

Zaki

Sadeh

Knorr

et al. 2023

Journal of Transplantation

View full text Add to dashboard Cite

Background. Nonadherence to immunosuppression in liver transplant recipients (LTRs) leads to deterioration in health outcomes. Once-dailyextended-release tacrolimus (TAC-ER) may improve adherence when compared to twice-dailyimmediate-release tacrolimus (TAC-IR). Methods. We conducted a randomized controlled study to evaluate medication adherence, clinical efficacy, and safety of TAC-ER in stable LTR. All patients >18 years who underwent liver transplantation before 6 months were eligible. Patients were randomized 1 : 1 to continued TAC-IR or conversion to TAC-ER. The primary outcome was change in medication adherence from baseline to 9 months, assessed using BAASIS. Secondary outcomes were tacrolimus trough levels, safety, and quality of life. Results. Thirty-one patients were consented and randomized to either of the two groups: conversion to TAC-ER (n = 15) or continued TAC-IR (n = 16). Six patients in the TAC-ER group withdrew after randomization due to apprehension about switching medication (n = 2), unwillingness to travel (n = 2), and increased liver tests after conversion (n = 2, both were acute rejections despite therapeutic tacrolimus levels and were considered unrelated to TAC-ER). We compared the results of nine patients in the TAC-ER group that completed the study with those of sixteen in the TAC-IR group. At baseline, there was no difference in tacrolimus trough levels between groups. Improved adherence was observed in the TAC-ER group as 100% of patients reported at least one period of full adherence during the study period (100% vs. 62.6%, p = 0.035 ). Tacrolimus trough levels and liver tests were comparable between groups throughout the study. There were no differences in eGFR, HbA1c, or QoL between the groups. Conclusion. TAC-ER improved medication adherence while maintaining comparable trough levels, liver function, and QoL as TAC-IR in LTR.

show abstract

“…Pese a que la evidencia de tacrólimus de liberación prolongada en el trasplante de páncreas es limitada, existen grupos que utilizan dicho fármaco (195).…”

Section: Terapia De Mantenimientounclassified

Influencia del trasplante de páncreas en la calidad de vida del paciente diabético con enfermedad renal crónica terminal: análisis de los resultados en una serie de 70 trasplantes consecutivos de páncreas – riñón

López-Sánchez¹

View full text Add to dashboard Cite

Utilization of LCP-Tacrolimus (Envarsus XR) in Simultaneous Pancreas and Kidney Transplant Recipients

Cited by 6 publications

References 9 publications

First World Consensus Conference on pancreas transplantation: Part II – recommendations

First World Consensus Conference on pancreas transplantation: Part II – recommendations

Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial

Influencia del trasplante de páncreas en la calidad de vida del paciente diabético con enfermedad renal crónica terminal: análisis de los resultados en una serie de 70 trasplantes consecutivos de páncreas – riñón

Contact Info

Product

Resources

About